Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10446)
All Articles published online
|
Publishing Process of This Article
|
Nov 7, 2020 (publication date) through Mar 8, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474 [PMID: 33244205 DOI: 10.3748/wjg.v26.i41.6455] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474 [PMID: 33244205 DOI: 10.3748/wjg.v26.i41.6455] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i41/6455.htm |
| Number | Citing Articles |
| 1 |
Xiaoxia Dong, Xiaoxiao Chen, Yuxiu Ren. MALT1 reflects inflammatory cytokines, disease activity, and its chronological change could estimate treatment response to infliximab in Crohn's disease patients. Journal of Clinical Laboratory Analysis 2022; 36(10) doi: 10.1002/jcla.24650
|
| 2 |
Zixuan He, Xianqin Huang, Dingyi Chen, Guoan Wang, Yuezhen Zhu, Huangqianyu Li, Sheng Han, Luwen Shi, Xiaodong Guan. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review. BMJ Global Health 2023; 8(11): e012780 doi: 10.1136/bmjgh-2023-012780
|
| 3 |
Yao Wu, Li-Bo Tao, Chang Liu, Fang-Xu Wang, Yi Yan, Shuang Sun. Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China. World Journal of Gastroenterology 2026; 32(8): 115291 doi: 10.3748/wjg.v32.i8.115291
Abstract(32) |
Core Tip(29) |
Full Article(HTML)(134)
|
Full Article with Cover (PDF)-4779K(13)
|
Audio-321K(6)
|
Peer-Review Report-267K(11)
|
Answering Reviewers-1305K(8)
|
Supplementary Material-228K(10)
|
Full Article (PDF)-4427K(35)
|
Full Article (XML)-107K(10)
|
Times Cited (0)
|
Total Visits (1331)
|
Open
|
| 4 |
Jian-Gao Fan, Ying Li, Ze Yu, Xing-Xian Luo, Ping Zheng, Xin Hao, Ze-Yuan Wang, Fei Gao, Guo-Qing Zhang, Wan-Yu Feng. Effectiveness and Economic Evaluation of Polyene Phosphatidyl Choline in Patients With Liver Diseases Based on Real-World Research. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.806787
|